Initial pediatric subject shows sustained benefit with QRX003; second patient approved for full-body treatment in ongoing ...

*© 2025 Insider Inc. and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy.

Quoin Pharmaceuticals, Ltd.’s QNRX share price has dipped by 13.50%, which has investors questioning if this is right time to buy.

Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is ...

The Quoin is a hotel in a historic bank, with a cozy cocktail bar in the basement and an airy, modern restaurant on the main ...

ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and ...

ASHBURN, Va., April 02, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the ...

A long-awaited expansion at Marshall Browning Hospital has transformed a once-cramped rehab space into a full-scale ...

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome.

Quoin Pharmaceuticals (QNRX) announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome ...

QUOIN PHARMACEUTICALS ($QNRX) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.35 per share, beating estimates of -$0. ...